Table 1 ASVS baseline characteristics

Gender

 Male

41

37 (41.1)

30 (42.9)

 Female

59

53 (58.9)

40 (57.1)

Mean age, years (SD)

60.1 ± 12.8

60.7 ± 12.8

60.9 ± 13.6

Mean BMI, kg/m² (SD)

26.7 ± 4.58

26.6 ± 4.65

26.2 ± 4.32

Ethnic Group

 Chinese

71

64 (71.1)

51 (72.9)

 Malay

11

9 (10.0)

8 (11.4)

 Indian

16

16 (17.8)

10 (14.3)

 Others

2

1 (1.1)

1 (1.43)

Smoking

 Smoker

9

6 (6.7)

4 (5.71)

 Non-Smoker

84

78 (86.7)

63 (90.0)

 Former Smoker

7

6 (6.7)

3 (4.29)

Primary Symptoms

 Pain

37

32 (35.6)

24 (34.3)

 Aching

43

33 (36.7)

25 (35.7)

 Swelling

57

52 (57.8)

39 (55.7)

 Heaviness

46

45 (50.0)

29 (41.4)

 Burning

2

1 (1.1)

0 (0.00)

 Itch

26

24 (26.7)

14 (20.0)

 Others

30

4 (4.4)

22 (31.4)

Comorbidities

 Hypertension

45

40 (44.4)

31 (44.3)

 Hyperlipidemia

37

33 (36.7)

24 (34.3)

 Diabetes Mellitus

16

14 (15.6)

11 (15.7)

 Ischemic Heart Disease

6

5 (5.6)

4 (5.71)

CEAP category

 C2 (varicose veins)

24

20 (22.2)

15 (21.4)

 C3 (edema)

33

30 (33.3)

25 (35.7)

 C4a (pigmentation/eczema)

32

28 (31.1)

21 (30.0)

 C4b (lipodermatosclerosis)

4

4 (4.4)

3 (4.29)

 C5 (healed venous ulcer)

7

7 (7.8)

3 (4.29)

Duration of Varicose Veins (months), median (IQR)

24.00 (7.75–60.0)

24.00 (7.00–60.0)

24.0 (6.00 – 60.0)

Distribution of Truncal Endovenous Ablation

(n = 151 legs)

(n = 138 legs)

(n = 107 legs)

 GSV

49 (32.5%)

41 (29.7%)

35 (32.7)

 Bilateral GSV

96 (63.6%)

92 (66.7%)

68 (63.6)

 SSV

1 (0.7%)

1 (0.7%)

1 (0.93)

 Combined unilateral GSV and SSV or ATV

5 (3.3%)

4 (2.9%)

3 (2.80)

Total number of truncal veins treated

(n = 156 veins)

(n = 142 veins)

(n = 110veins)

 GSV

150 (96.2)

137 (96.5)

106 (96.4)

 SSV

5 (3.2)

4 (2.82)

4 (3.64)

 ATV

1 (0.6)

1 (0.7)

0 (0.0)